Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 862

1.

Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin.

Anderson GL, Chlebowski RT, Rossouw JE, Rodabough RJ, McTiernan A, Margolis KL, Aggerwal A, David Curb J, Hendrix SL, Allan Hubbell F, Khandekar J, Lane DS, Lasser N, Lopez AM, Potter J, Ritenbaugh C.

Maturitas. 2006 Sep 20;55(2):103-15. Epub 2006 Jul 11.

PMID:
16815651
2.

Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial.

McTiernan A, Martin CF, Peck JD, Aragaki AK, Chlebowski RT, Pisano ED, Wang CY, Brunner RL, Johnson KC, Manson JE, Lewis CE, Kotchen JM, Hulka BS; Women's Health Initiative Mammogram Density Study Investigators.

J Natl Cancer Inst. 2005 Sep 21;97(18):1366-76.

PMID:
16174858
3.

Post-menopausal hormone replacement therapy (cont'd): risk-benefit balance in the hot seat.

[No authors listed]

Prescrire Int. 2004 Jun;13(71):106-9.

PMID:
15233153
4.
5.

Estrogen plus progestin and the risk of peripheral arterial disease: the Women's Health Initiative.

Hsia J, Criqui MH, Rodabough RJ, Langer RD, Resnick HE, Phillips LS, Allison M, Bonds DE, Masaki K, Caralis P, Kotchen JM; Women's Health Initiative Investigators.

Circulation. 2004 Feb 10;109(5):620-6.

6.

Cardiovascular risk in women with non-specific chest pain (from the Women's Health Initiative Hormone Trials).

Robinson JG, Wallace R, Limacher M, Ren H, Cochrane B, Wassertheil-Smoller S, Ockene JK, Blanchette PL, Ko MG.

Am J Cardiol. 2008 Sep 15;102(6):693-9. doi: 10.1016/j.amjcard.2007.12.044. Epub 2008 Jul 2.

PMID:
18773990
7.

New evidence regarding hormone replacement therapies is urgently required transdermal postmenopausal hormone therapy differs from oral hormone therapy in risks and benefits.

Modena MG, Sismondi P, Mueck AO, Kuttenn F, Lignières Bd, Verhaeghe J, Foidart JM, Caufriez A, Genazzani AR; TREAT.

Maturitas. 2005 Sep 16;52(1):1-10. Review.

8.

Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative.

Barnabei VM, Cochrane BB, Aragaki AK, Nygaard I, Williams RS, McGovern PG, Young RL, Wells EC, O'Sullivan MJ, Chen B, Schenken R, Johnson SR; Women's Health Initiative Investigators.

Obstet Gynecol. 2005 May;105(5 Pt 1):1063-73.

PMID:
15863546
9.

Estrogen plus progestin and the risk of coronary heart disease.

Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Trevisan M, Black HR, Heckbert SR, Detrano R, Strickland OL, Wong ND, Crouse JR, Stein E, Cushman M; Women's Health Initiative Investigators.

N Engl J Med. 2003 Aug 7;349(6):523-34.

10.

Breast Cancer After Use of Estrogen Plus Progestin and Estrogen Alone: Analyses of Data From 2 Women's Health Initiative Randomized Clinical Trials.

Chlebowski RT, Rohan TE, Manson JE, Aragaki AK, Kaunitz A, Stefanick ML, Simon MS, Johnson KC, Wactawski-Wende J, O'Sullivan MJ, Adams-Campbell LL, Nassir R, Lessin LS, Prentice RL.

JAMA Oncol. 2015 Jun;1(3):296-305. doi: 10.1001/jamaoncol.2015.0494.

PMID:
26181174
11.

Conjugated equine estrogen and risk of benign proliferative breast disease: a randomized controlled trial.

Rohan TE, Negassa A, Chlebowski RT, Habel L, McTiernan A, Ginsberg M, Wassertheil-Smoller S, Page DL.

J Natl Cancer Inst. 2008 Apr 16;100(8):563-71. doi: 10.1093/jnci/djn075. Epub 2008 Apr 8. Erratum in: J Natl Cancer Inst. 2008 May 21;100(10):754.

PMID:
18398105
12.

Postmenopausal hormone therapy: cardiovascular risks.

[No authors listed]

Prescrire Int. 2003 Apr;12(64):65-9.

PMID:
12674130
13.

Incidence of cervical cytological abnormalities with aging in the women's health initiative: a randomized controlled trial.

Yasmeen S, Romano PS, Pettinger M, Johnson SR, Hubbell FA, Lane DS, Hendrix SL.

Obstet Gynecol. 2006 Aug;108(2):410-9.

PMID:
16880313
14.

Postmenopausal estrogen-containing hormone therapy and the risk of breast cancer.

Jick SS, Hagberg KW, Kaye JA, Jick H.

Obstet Gynecol. 2009 Jan;113(1):74-80. doi: 10.1097/AOG.0b013e31818fdde4.

PMID:
19104362
15.

Estrogen-progestin replacement therapy and breast cancer risk: the Women's Health Study (United States).

Porch JV, Lee IM, Cook NR, Rexrode KM, Burin JE.

Cancer Causes Control. 2002 Nov;13(9):847-54.

PMID:
12462550
16.

Estrogen plus progestin and colorectal cancer in postmenopausal women.

Chlebowski RT, Wactawski-Wende J, Ritenbaugh C, Hubbell FA, Ascensao J, Rodabough RJ, Rosenberg CA, Taylor VM, Harris R, Chen C, Adams-Campbell LL, White E; Women's Health Initiative Investigators.

N Engl J Med. 2004 Mar 4;350(10):991-1004.

18.

Breast cancer risk with postmenopausal hormonal treatment.

Collins JA, Blake JM, Crosignani PG.

Hum Reprod Update. 2005 Nov-Dec;11(6):545-60. Epub 2005 Sep 8. Review. Erratum in: Hum Reprod Update. 2006 May-Jun;12(3):331.

PMID:
16150813
19.

Recent epidemiological evidence relevant to the clinical management of the menopause.

Shapiro S.

Climacteric. 2007 Oct;10 Suppl 2:2-15. Review.

PMID:
17882666
20.

Colorectal cancer incidence and postmenopausal hormone use by type, recency, and duration in cancer prevention study II.

Hildebrand JS, Jacobs EJ, Campbell PT, McCullough ML, Teras LR, Thun MJ, Gapstur SM.

Cancer Epidemiol Biomarkers Prev. 2009 Nov;18(11):2835-41. doi: 10.1158/1055-9965.EPI-09-0596. Epub 2009 Oct 20.

Supplemental Content

Support Center